COVID-19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and is modified by dexamethasone

We performed comparative lower respiratory tract transcriptional profiling of 52 critically ill patients with the acute respiratory distress syndrome (ARDS) from COVID-19 or from other etiologies, as well as controls without ARDS. In contrast to a cytokine storm, we observed reduced proinflammatory gene expression in COVID-19 ARDS when compared to ARDS due to other causes. COVID-19 ARDS was characterized by a dysregulated host response with increased PTEN signaling and elevated expression of genes with non-canonical roles in inflammation and immunity that were predicted to be modulated by dexamethasone and granulocyte colony stimulating factor. Compared to ARDS due to other types of viral pneumonia, COVID-19 was characterized by impaired interferon-stimulated gene expression (ISG). We found that the relationship between SARS-CoV-2 viral load and expression of ISGs was decoupled in patients with COVID-19 ARDS when compared to patients with mild COVID-19. In summary, assessment of host gene expression in the lower airways of patients with COVID-19 ARDS did not demonstrate cytokine storm but instead revealed a unique and dysregulated host response predicted to be modified by dexamethasone.

[1]  Irving L. Weissman,et al.  A molecular cell atlas of the human lung from single cell RNA sequencing , 2019, Nature.

[2]  Roland Eils,et al.  COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis , 2020, Nature Biotechnology.

[3]  N. Neff,et al.  Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses , 2020, Nature Communications.

[4]  Aditya M. Rao,et al.  Multi-cohort analysis of host immune response identifies conserved protective and detrimental modules associated with severity irrespective of virus , 2020, medRxiv.

[5]  Judith B. Zaugg,et al.  Data-driven hypothesis weighting increases detection power in genome-scale multiple testing , 2016, Nature Methods.

[6]  M. Balaan,et al.  Acute Respiratory Distress Syndrome , 2016, Critical care nursing quarterly.

[7]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[8]  Andreas Krämer,et al.  Causal analysis approaches in Ingenuity Pathway Analysis , 2013, Bioinform..

[9]  F. Brunkhorst,et al.  Sepsis-3 , 2017, Der Internist.

[10]  I. Amit,et al.  Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients , 2020, Cell.

[11]  Jun Chen,et al.  STAT6/Arg1 promotes microglia/macrophage efferocytosis and inflammation resolution in stroke mice. , 2019, JCI insight.

[12]  K. Jacobson,et al.  UDP-glucose promotes neutrophil recruitment in the lung , 2016, Purinergic Signalling.

[13]  Matthew Stephens,et al.  False discovery rates: a new deal , 2016, bioRxiv.

[14]  Katherine S. Pollard,et al.  Integrating host response and unbiased microbe detection for lower respiratory tract infection diagnosis in critically ill adults , 2018, Proceedings of the National Academy of Sciences.

[15]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[16]  Jae-Rin Lee,et al.  Regulation of inflammatory gene expression in macrophages by epithelial-stromal interaction 1 (Epsti1). , 2017, Biochemical and biophysical research communications.

[17]  B. Binder,et al.  Myeloid PTEN Promotes Inflammation but Impairs Bactericidal Activities during Murine Pneumococcal Pneumonia , 2010, The Journal of Immunology.

[18]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[19]  Fabian J Theis,et al.  SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes , 2020, Nature Medicine.

[20]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[21]  M. Kaplan,et al.  STAT signaling in inflammation , 2013, JAK-STAT.

[22]  Baptiste Jaquemet,et al.  The new deal , 2005, SIGGRAPH '05.

[23]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Guo,et al.  The functions of tumor suppressor PTEN in innate and adaptive immunity , 2017, Cellular &Molecular Immunology.

[25]  M. Robinson,et al.  Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences , 2015, F1000Research.

[26]  H. Maecker,et al.  Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis , 2020, medRxiv.

[27]  P. Mehta,et al.  COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.

[28]  M. Singer,et al.  Sepsis therapies: learning from 30 years of failure of translational research to propose new leads , 2020, EMBO molecular medicine.

[29]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[30]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[31]  Marc Salit,et al.  Evaluation of the External RNA Controls Consortium (ERCC) reference material using a modified Latin square design , 2016, bioRxiv.

[32]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[33]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .